Neurogene Inc. Overview
Pro stress-test →Neurogene is a clinical-stage biotechnology company building a product portfolio of genetic medicines for rare neurological diseases through its proprietary transgene regulation technology called EXACT (Expression Attenuation via Construct Tuning). The company's lead program NGN-401 received FDA Breakthrough Therapy designation for Rett syndrome, with interim Phase 1/2 data demonstrating clinically meaningful improvements across multiple functional domains.
Strategic Profile
Pro stress-test →Neurogene is on track to complete dosing in its Embolden registrational trial by Q2 2026 and plans to present additional interim clinical data in mid-2026. The stock carries a Strong Buy rating with an average price target of $48.33, positioning the company as a significant player in gene therapy for untreatable neurological disorders.
Competitive Landscape
Pro stress-test →Neurogene competes in the gene therapy space for rare neurological diseases against companies including Taysha Gene Therapies, Passage Bio, and emerging gene therapy developers. Its competitive advantage lies in the proprietary EXACT platform, which addresses limitations of conventional gene therapy approaches for conditions with limited treatment options.
Industry Context
Neurogene Inc. operates in Biotechnology - Gene Therapy.
Key facts
Founded: 2018 · Headquarters: New York, NY · Employees: 107 · Revenue: $0 · Market cap: $306M